P-186 - EFFECT OF ABROCITINIB (ABR) ON THE PHARMACOKINETICS OF PROBE DRUGS [DABIGATRAN ETEXILATE (DE), ROSUVASTATIN (ROS), METFORMIN (MET)] AND ENDOGENOUS BIOMARKERS FOR DRUG TRANSPORTERS.

M. Vourvahis¹, W. Byon², C. Chang², V. Le³, L. Luo², S. Mathialagan², M. Dowty⁴, A. Rodrigues², B. Malhotra¹; ¹Pfizer Inc., New York, NY, USA, ²Pfizer Inc., Groton, CT, USA, ³Pfizer Inc., Collegeville, PA, USA, ⁴Pfizer Inc., Cambridge, MA, USA.